Furthermore, Cox proportional hazards regression analysis indicated that patients over 65 years of age were 1.85 times more likely to die of cancer than those under 65 years of age (P < 0.001; HR, 1.85; 95% CI, 1.41–2.43); patients with UICC stage III/IV were 3.09 times more likely to die of cancer than those with UICC stage I/II (P < 0.001; HR, 3.09; 95% CI, 2.34–4.07); patients with serum CEA ≥ 5 ng/ml were 2.28 times more likely to die of cancer than those whose serum CEA <5 ng/ml (P < 0.001; HR, 2.28; 95% CI, 1.73–3.01) for overall survival. This evidence concerns the gene CEACAM5 and cancer.